---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-007222"
form_type: "8-K"
ticker: "FLNA"
cik: "0001069530"
company_name: "FILANA THERAPEUTICS, INC."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T20:52:53.185609+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cassava Sciences Q3 net loss $10.8M; advances simufilam for TSC epilepsy

## Summary
- Net loss of $10.8M ($0.22/share) vs $27.9M loss ($0.58) in Q3 2024; cash $106.1M.
- Simufilam proof-of-concept study for TSC-related epilepsy expected to begin H1 2026.
- Appointed Joseph Hulihan as CMO (August 2025) and Dawn C. Bir to board (October 2025).
- Maintains $31.25M loss contingency for securities litigation settlement; timing unclear.
- Cash use guidance for second half 2025 revised downward; year-end cash est. $92-$96M.

## SEC filing metadata
- accession: 0001171843-25-007222
- form_type: 8-K
- ticker: FLNA
- cik: 0001069530
- company_name: FILANA THERAPEUTICS, INC.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069530/000117184325007222/0001171843-25-007222-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069530/000117184325007222/f8k_111225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-007222
- JSON: https://secwatch.observer/filing/0001171843-25-007222.json
- Plain text: https://secwatch.observer/filing/0001171843-25-007222.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.